Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Evogene Ltd. Regulatory Filings 2024

Feb 28, 2024

6785_rns_2024-02-28_df8805e7-c8a2-412f-964d-69ec6a536679.htm

Regulatory Filings

Open in viewer

Opens in your device viewer

_________ false

����� ��"� 2 381
EVOGENE LTD
Corporation no: 512838723 13041
- - -
Israel Securities Authority Tel Aviv Stock Exchange C003 ( Public ) Reported via MAGNA: 28/02/2024
www.isa.gov.il www.tase.co.il Reference: 2024-02-020394 Time of broadcast: 12:44 12:44

The corporation scheduled the publication of the report to 28/02/2024 14:00Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements

LAVIE_BIO_CORTEVA_FINAL_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1 Date of revision of form structure: 20/02/2024
Address: Gad Feinstein St 13, P.O.B 2100 , Rehovot 76121   , Tel: 08-9311900 , Fax: 08-9466724
E-mail address: [email protected]   Company site: www.evogene.com
Previous names of reporting entity:
Name of the Signatory: Kofman Guy Position of Signatory in the reporting corporation: Lawyer/ Legal Counsel Name of Employer Company:
Address: Gad Feinstein St. 13 , Rehovot 7638517 Telephone: 08-9311962 Facsimile: 08-9466724 E-mail: [email protected] 1